Auto-discovered from 3 recent studies; not yet curated.
ReviewTrialInconclusiveLimited evidenceTier 4 · clinicaln = 11
Revista colombiana de obstetricia y ginecologia · Jun 2024 · expert consensus / practice guideline based on literature review
This paper is an expert consensus, not a clinical study of a single drug. Eleven specialists reviewed the literature and issued recommendations for managing advanced or metastatic high-grade epithelial ovarian cancer, including surgery, chemotherapy, genetic testing, bevacizumab, and PARP inhibitors. It does not report new patient outcomes from a trial. The document mainly summarizes what the panel suggested based on existing guidelines and evidence.
Studied with: platinum-based chemotherapy, bevacizumab, paclitaxel, carboplatin.
Key findings
- The panel suggested primary cytoreductive surgery as the initial approach when complete resection is feasible.
- Neoadjuvant chemotherapy followed by interval surgery was suggested when complete cytoreduction is unlikely or the patient has poor functional status/comorbidities.
- Bevacizumab was suggested with platinum-based chemotherapy for high-risk disease, with maintenance only if it was part of first-line therapy.
- PARP inhibitors (olaparib, niraparib, rucaparib) were suggested as maintenance in selected BRCA/HRD-defined groups.
- For platinum-resistant relapse, sequential non-platinum single-agent chemotherapy and best supportive care for poor performance status were suggested.
Limitations: This is a consensus statement/practice guideline, not an original comparative trial.; No new efficacy or safety data are reported in the abstract.; Recommendations are based on literature review and expert agreement, so they are subject to guideline-selection and expert-opinion bias.; The abstract does not provide patient-level outcomes, follow-up, or effect estimates.; Several recommendations are conditional/suggested rather than based on direct evidence from this paper..
Provides management recommendations for advanced/metastatic epithelial ovarian cancer, including several anticancer agents and maintenance strategies.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Case reportMechanismReported positiveLimited evidenceTier 3 · early humann = 1
Journal of medical case reports · Aug 2023 · case report
PaclitaxelCarboplatinOlaparibfallopian tube cancerhigh-grade serous carcinomabreast cancerovarian neoplasmshereditary breast and ovarian cancer syndrome A 72-year-old woman underwent hysterectomy and bilateral salpingo-oophorectomy for presumed benign disease; detailed pathology revealed incidental high-grade serous carcinoma of the right fallopian tube. Staging surgery found a single para-aortic node metastasis, a germline BRCA2 mutation was detected, she received six courses of paclitaxel plus carboplatin followed by maintenance olaparib, and she was disease-free 18 months after surgery.
Reported effects: adjuvant chemotherapy courses 6, n=1 · disease-free at 18 mo, n=1
Studied with: paclitaxel and carboplatin.
Key findings
- Incidental detection of high-grade serous carcinoma of the right fallopian tube on detailed pathological examination.
- Staging laparotomy confirmed a single para-aortic lymph node metastasis (FIGO Stage IIIA1(i)).
- Postoperative detection of a germline BRCA2 mutation and diagnosis of hereditary breast and ovarian cancer syndrome.
- Patient received adjuvant therapy: six courses of paclitaxel and carboplatin followed by maintenance olaparib.
- Patient was free of disease 18 months after surgery.
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group to assess treatment effect.; Relatively short follow-up (reported disease-free status at 18 months only).; No dosing details provided for chemotherapy or olaparib in the abstract..
Illustrates that detailed pathologic examination and accurate staging can identify occult fallopian tube cancer and that germline BRCA2 testing may inform use of maintenance PARP inhibitor therapy.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human · observationalReported positiveLimited evidenceTier 3 · early humann = 58
Journal of experimental & clinical cancer research : CR · May 2023
The authors screened 58 individuals with uterine leiomyosarcoma for homologous recombination deficiency (HRD) and identified 5 cases (9%). All five accessed PARP inhibitor therapy; in three patients with mature follow-up two achieved a complete response or durable partial response after platinum was added to PARPi. In patient-derived xenografts, the PARP1-specific inhibitor AZD5305 produced the most rapid, complete and sustained responses compared with olaparib or olaparib plus cisplatin, including in a BRCA2-deleted PDX that had developed PARPi-resistance mutations.
Reported effects: WGS samples with COSMIC signature 3 13, n=13 · WGS samples with high genome-wide LOH (> 0.2) 11, n=13 · +4 more
Studied with: cisplatin.
Key findings
- All 13 uLMS samples analysed by WGS had a dominant COSMIC mutational signature 3.
- 11 of the 13 WGS samples had high genome-wide loss of heterozygosity (> 0.2).
- Only two WGS samples had a CHORD score > 50%; one of these had a homozygous pathogenic BRCA2 deletion.
- A further three samples harboured homozygous HRD alterations (all deletions in BRCA2) detected by WES or panel sequencing, giving 5/58 (9%) individuals with HRD uLMS.
- All five individuals with HRD gained access to PARPi therapy; two of three with mature clinical follow-up achieved a complete response or durable partial response after platinum was added to PARPi upon minor progression.
- In corresponding PDX models, AZD5305 produced the most rapid, complete and sustained responses compared with olaparib alone or olaparib plus cisplatin, including in a BRCA2-deleted PDX that had developed PARPi-resistance mutations in PRKDC (DNA-PKcs).
Limitations: Small number of HRD cases (5 of 58), with only three patients having mature clinical follow-up.; Non-randomized, observational access to PARPi in patients (no control arm reported).; PDX (preclinical) findings may not fully predict clinical efficacy.; Sequencing methods varied across samples (WGS, WES, panel), and some genomic HRD metrics (CHORD) were discordant.; No dosing, schedule, or detailed treatment-response durations provided in the abstract..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 295
The Lancet. Oncology · May 2021 · double-blind, randomised, placebo-controlled, phase 3 trial
Olaparibovarian cancerhigh-grade serous ovarian cancerhigh-grade endometrioid ovarian cancerprimary peritoneal cancerfallopian tube cancer This phase 3 study tested olaparib tablets as maintenance therapy in people with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation. In the final analysis, the olaparib group had a longer median overall survival than the placebo group, but the difference did not reach conventional statistical significance. More serious side effects, including anemia, were reported with olaparib.
Reported effects: Median overall survival 51.7 mo [41.5–59.1], n=196 · Median overall survival 38.8 mo [31.4–48.6], n=99 · +1 more
Key findings
- Median overall survival was 51.7 months with olaparib versus 38.8 months with placebo.
- The hazard ratio for overall survival was 0.74 with a 95% CI of 0.54 to 1.00; p=0.054.
- Grade 3 or worse anemia occurred in 21% of patients receiving olaparib and 2% receiving placebo.
- Serious treatment-emergent adverse events occurred in 26% of patients receiving olaparib and 8% receiving placebo.
- Fatal treatment-emergent adverse events occurred in 4% of patients receiving olaparib; 6 deaths were judged treatment-related.
Limitations: Overall survival difference did not reach statistical significance (p=0.054).; Overall survival was unadjusted for subsequent PARP inhibitor therapy in 38% of placebo patients, which may confound interpretation.; Safety and efficacy are from a single randomized trial population with BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer, limiting generalizability.; The abstract does not provide subgroup analyses or long-term quality-of-life outcomes..
Maintenance olaparib was evaluated for its effect on overall survival in relapsed BRCA1/2-mutated ovarian cancer.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 391
The New England journal of medicine · Dec 2018 · international randomized double-blind phase 3 trial
Olaparibadvanced ovarian cancerhigh-grade serous ovarian cancerendometrioid ovarian cancerprimary peritoneal cancerfallopian-tube cancer This randomized phase 3 trial tested olaparib as maintenance therapy after platinum-based chemotherapy in women with newly diagnosed advanced BRCA1/2-mutated ovarian, primary peritoneal, or fallopian-tube cancer. After a median follow-up of 41 months, women assigned to olaparib had a longer progression-free survival than those assigned to placebo. The abstract also reports more patients were free of disease progression and death at 3 years in the olaparib group. Adverse events were said to be consistent with the known toxic effects of olaparib.
Reported effects: Kaplan-Meier estimate of the rate of freedom from disease progression and from death at 3 years 60%, n=391 · hazard ratio for disease progression or death 0.3 [0.23–0.41], p <0.001, n=391
Studied with: platinum-based chemotherapy.
Key findings
- Olaparib maintenance was associated with a lower risk of disease progression or death than placebo.
- 3-year freedom from disease progression and death was higher with olaparib than placebo (60% vs. 27%).
- Adverse events were consistent with the known toxic effects of olaparib.
Limitations: Progression-free survival was the primary endpoint; overall survival is not reported in the abstract.; Follow-up was median 41 months, so longer-term outcomes are not fully described here.; Adverse events are summarized only briefly in the abstract..
Maintenance olaparib was evaluated in a randomized trial in newly diagnosed advanced BRCA1/2-mutated gynecologic cancers.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Cancers where Olaparib reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Human evidence
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group to assess treatment effect.; Relatively short follow-up (reported disease-free status at 18 months only).; No dosing details provided for chemotherapy or olaparib in the abstract.; Overall survival difference did not reach statistical significance (p=0.054).; Overall survival was unadjusted for subsequent PARP inhibitor therapy in 38% of placebo patients, which may confound interpretation..
Cited positive studies (2)
Limitations: Overall survival difference did not reach statistical significance (p=0.054).; Overall survival was unadjusted for subsequent PARP inhibitor therapy in 38% of placebo patients, which may confound interpretation.; Safety and efficacy are from a single randomized trial population with BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer, limiting generalizability.; The abstract does not provide subgroup analyses or long-term quality-of-life outcomes.; Progression-free survival was the primary endpoint; overall survival is not reported in the abstract.; Follow-up was median 41 months, so longer-term outcomes are not fully described here..
Cited positive studies (2)
Primary peritoneal cancer2 positive2 human
Limitations: Overall survival difference did not reach statistical significance (p=0.054).; Overall survival was unadjusted for subsequent PARP inhibitor therapy in 38% of placebo patients, which may confound interpretation.; Safety and efficacy are from a single randomized trial population with BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer, limiting generalizability.; The abstract does not provide subgroup analyses or long-term quality-of-life outcomes.; Progression-free survival was the primary endpoint; overall survival is not reported in the abstract.; Follow-up was median 41 months, so longer-term outcomes are not fully described here..
Cited positive studies (2)
Limitations: Small number of HRD cases (5 of 58), with only three patients having mature clinical follow-up.; Non-randomized, observational access to PARPi in patients (no control arm reported).; PDX (preclinical) findings may not fully predict clinical efficacy.; Sequencing methods varied across samples (WGS, WES, panel), and some genomic HRD metrics (CHORD) were discordant.; No dosing, schedule, or detailed treatment-response durations provided in the abstract..
Cited positive studies (1)
Limitations: Overall survival difference did not reach statistical significance (p=0.054).; Overall survival was unadjusted for subsequent PARP inhibitor therapy in 38% of placebo patients, which may confound interpretation.; Safety and efficacy are from a single randomized trial population with BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer, limiting generalizability.; The abstract does not provide subgroup analyses or long-term quality-of-life outcomes..
Cited positive studies (1)
Limitations: Overall survival difference did not reach statistical significance (p=0.054).; Overall survival was unadjusted for subsequent PARP inhibitor therapy in 38% of placebo patients, which may confound interpretation.; Safety and efficacy are from a single randomized trial population with BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer, limiting generalizability.; The abstract does not provide subgroup analyses or long-term quality-of-life outcomes..
Cited positive studies (1)
Limitations: Progression-free survival was the primary endpoint; overall survival is not reported in the abstract.; Follow-up was median 41 months, so longer-term outcomes are not fully described here.; Adverse events are summarized only briefly in the abstract..
Cited positive studies (1)
Limitations: Progression-free survival was the primary endpoint; overall survival is not reported in the abstract.; Follow-up was median 41 months, so longer-term outcomes are not fully described here.; Adverse events are summarized only briefly in the abstract..
Cited positive studies (1)
Fallopian-tube cancer1 positive1 human
Limitations: Progression-free survival was the primary endpoint; overall survival is not reported in the abstract.; Follow-up was median 41 months, so longer-term outcomes are not fully described here.; Adverse events are summarized only briefly in the abstract..
Cited positive studies (1)
Preclinical only: lab / animal (4)
High-grade serous carcinoma1 positive
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group to assess treatment effect.; Relatively short follow-up (reported disease-free status at 18 months only).; No dosing details provided for chemotherapy or olaparib in the abstract..
Cited positive studies (1)
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group to assess treatment effect.; Relatively short follow-up (reported disease-free status at 18 months only).; No dosing details provided for chemotherapy or olaparib in the abstract..
Cited positive studies (1)
Ovarian neoplasms1 positive
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group to assess treatment effect.; Relatively short follow-up (reported disease-free status at 18 months only).; No dosing details provided for chemotherapy or olaparib in the abstract..
Cited positive studies (1)
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group to assess treatment effect.; Relatively short follow-up (reported disease-free status at 18 months only).; No dosing details provided for chemotherapy or olaparib in the abstract..
Cited positive studies (1)
Evidence at a glance: Olaparib by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.